Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Flush Clear all
Recruiting Phase 2 Interventional

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT05686226
View directory record Official record
Conditions
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Recruiting Phase 2 Interventional

CEUS Evaluation of Hydrocephalus in Neonates and Infants

NCT06693752
View directory record Official record
Conditions
Hydrocephalus in Infants, Hydrocephalus Acquired
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 18 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen

NCT05821309
View directory record Official record
Conditions
Constipation
Interventions
PEG 3350, PEG-3350 with electrolytes, Glycerin
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Recruiting Not applicable Interventional

A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery

NCT04891510
View directory record Official record
Conditions
Mastectomy, Mammaplasty, Breast Reconstruction
Interventions
REVOLVE Advanced Adipose System, LipoGrafter, Viality
Device · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT00862459
View directory record Official record
Conditions
Brain Diseases, Spinal Cord Diseases
Interventions
Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

NCT01070979
View directory record Official record
Conditions
Hormone Replacement Therapy
Interventions
Estradiol acetate, Estradiol, Conjugated equine estrogens
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
32
States / cities
Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Not applicable Interventional Results available

Heart Rate Response to Regadenoson and Sudden Cardiac Death

NCT01842035
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
Interventions
regadenoson
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 1 Interventional Results available

Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

NCT01161121
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
adenosine, regadenoson
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Jacksonville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ureteral Patency in the Post-indigo Carmine Era

NCT02677623
View directory record Official record
Conditions
Ureteral Patency
Interventions
Pyridium, Sodium Fluorescein, Mannitol, Normal Saline
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Not applicable Interventional

Follicular Flushing

NCT01558141
View directory record Official record
Conditions
Fertilization
Interventions
Aspiration without flushing follicles with culture media, Follicular Flushing
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 7, 2026, 8:42 PM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

NCT05366179
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CAR.B7-H3T cells infusion
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Protein Loading on Measurement of Renal Reserve

NCT07335614
View directory record Official record
Conditions
Glomerular Filtration Rate
Interventions
Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

3-D Transcranial Ultrasound Analysis Study

NCT00239525
View directory record Official record
Conditions
Cerebrovascular Accident, Intracranial Hypertension
Interventions
3-D ultrasound scanner, Perflutren Protein-Type A Microspheres for injection
Device · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 7, 2026, 8:42 PM EDT
Completed No phase listed Observational

Wound Necrosis in Lower Extremity Surgery

NCT03351387
View directory record Official record
Conditions
Extremity Lower Wounds
Interventions
SPY Intra-operative Angiography
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

NCT00799604
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

NCT00206622
View directory record Official record
Conditions
Hot Flashes
Interventions
Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2009 · Synced Sep 7, 2026, 8:42 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

NCT04104659
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MK 6240
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Not applicable Interventional

Effect of an Opioid Disposal Pouch Versus Usual Care on Post Discharge Disposal of Unused Medication

NCT04553588
View directory record Official record
Conditions
Drug Prescriptions
Interventions
Disposal pouch
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 7, 2026, 8:42 PM EDT
Not yet recruiting Phase 4 Interventional

Flush, Lyse, Operate

NCT07592520
View directory record Official record
Conditions
Complicated Parapneumonic Effusion, Empyema, Pleural
Interventions
Intrapleural Saline with possible escalation to intraplerual alteplase and dornase.
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 7, 2026, 8:42 PM EDT
Not listed Phase 3 Interventional

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

NCT05799248
View directory record Official record
Conditions
Prostate Cancer
Interventions
rhPSMA-7.3 (18F)
Drug
Lead sponsor
MidLantic Urology
Other
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

NCT03497442
View directory record Official record
Conditions
Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions
Brimonidine Tartrate, Placebo Vehicle Gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 7, 2026, 8:42 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of a Disposable Flexible Bronchoscope, aScope IV

NCT02255838
View directory record Official record
Conditions
Respiratory Insufficiency, Pneumonia, Atelectasis
Interventions
Bronchoscope reusable (Storz 8402 2x), Bronchoscope disposable (aScope 4)
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

NCT01578239
View directory record Official record
Conditions
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
Interventions
Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 7, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Results available

A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children

NCT02435069
View directory record Official record
Conditions
Fecal Incontinence, Neurogenic Bowel
Interventions
Dose Response - NS and USP Glycerin - First Intervention, Effectiveness - NS and USP Glycerin - Second Intervention
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 7, 2026, 8:42 PM EDT